Oncology Corporate Profile
Alchemia Limited is a listed Australian biopharmaceutical company (ASX:ACL) with an FDA approved drug (Fondaparinux sodium) and a late stage oncology product pipeline derived from the HyACT platform. In addition, Alchemia has a proprietary drug discovery platform, VAST®, derived from Alchemia’s chemistry expertise.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|irinotecan||topoisomerase I inhibitor||Colorectal cancer||III|
|irinotecan||topoisomerase I inhibitor||Small Cell Lung Cancer (SCLC)||II|